AbbVie vs Johnson & Johnson
Johnson & Johnson reported revenue of $94.2 billion in fiscal 2025, 1.5 times AbbVie's $61.2 billion in fiscal 2025. AbbVie's revenue grew 8.6% in its latest year, and Johnson & Johnson's grew 6.0%. Free cash flow was $17.8 billion at AbbVie and $19.7 billion at Johnson & Johnson. Their fiscal years end in different months (December 31 and December 28), so the periods don't line up exactly.
Side by side
| AbbVie | Johnson & Johnson | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 28, 2025 |
| Revenue | $61.2B | $94.2B |
| Revenue growth | 8.6% | 6.0% |
| Revenue growth a year, last 5 years | 6.0% | 2.7% |
| Gross margin | 70.2% | 67.9% |
| Operating margin | 24.6% | — |
| Net margin | 6.9% | 28.5% |
| Free cash flow | $17.8B | $19.7B |
| Free cash flow margin | 29.1% | 20.9% |
| Return on capital | 15.7% | 28.6% |
| Net debt to EBITDA | 2.7x | 0.7x |
| Dividends and buybacks | $12.6B | $18.3B |
| Change in diluted share count | 0.0% | 0.0% |
| Last close | $283.54 | $267.14 |
| P/E at the last close | 48.8× | 40.5× |
| Insider trades, last 12 months | sold $30.8 million | bought $257,688, sold $154.4 million |
| Piotroski F-score | 7 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AbbVieJohnson & Johnson
Operating margin
Percent of revenue
AbbVieJohnson & Johnson
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbbVieJohnson & Johnson
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AbbVie and Johnson & Johnson pages.